Contents
Part 1 · Preliminary
1Name#
(1)This instrument is the National Health (Minimum Stockholding) Determination 2023.
(2)This instrument may also be cited as PB 65 of 2023.
4Definitions#
In this instrument:
data collection period has the same meaning as in the National Health (Pharmaceutical Benefits) Regulations 2017.
pharmaceutical benefit has the same meaning as in Part VII of the Act.
pharmaceutical item has the same meaning as in Part VII of the Act.
pricing quantity has the same meaning as in Part VII of the Act.
usual demand, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.
usual PBS demand, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.
5Usual PBS demand#
(1)The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (the reference period) before the previous data collection period for the brand divided by the number of months in the reference period.
(2)For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:
(a)the number of packs of the brand supplied as pharmaceutical benefits during that period; and
(b)adjusted as if the size of the pack equals the pricing quantity of the brand.
(3)For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.
Part 2 · Minimum stockholding requirement
6Applicable quantity of a brand of a pharmaceutical item#
For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.
Schedule 1 · Applicable quantity of a brand of a pharmaceutical item
Note: See section 6.
| Applicable quantity of a brand of a pharmaceutical item | ||||
|---|---|---|---|---|
| Column 1Drug | Column 2Form | Column 3Manner of administration | Column 4Brand | Column 5Applicable quantity |
| Acarbose | Tablet 100 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Allosig | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | APO-ALLOPURINOL | 6 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | Zyloprim | 4 months stock by reference to usual demand |
| Amifampridine | Tablet 10 mg | Oral | Ruzurgi | 6 months stock by reference to usual PBS demand |
| Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides | Oral powder 400 g (Essential Care Jr) | Oral | Essential Care Jr | 6 months stock by reference to usual PBS demand |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | 0 months stock by reference to usual PBS demand |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX-Amitriptyline | 5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX-Amitriptyline | 4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | 4.5 months stock by reference to usual demand |
| Amlodipine | Tablet 10 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand of both APX-AMLODIPINE and Amlodipine APOTEX added together |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand |
| Amoxicillin | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | Amoxil | between 1 June 2026 to 30 November 2026—0 months stock by reference to usual demand |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |
| Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | 6 months stock by reference to usual demand |
| Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte Viatris | 6 months stock by reference to usual demand |
| Amphotericin B | Lozenge 10 mg | Oral | Fungilin | 4 months stock by reference to usual PBS demand |
| Anakinra | Injection 100 mg in 0.67 mL single use pre-filled syringe | Injection | Kineret | 6 months stock by reference to usual PBS demand |
| Aripiprazole | Tablet 10 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 10 mg | Oral | ARIPIPRAZOLE-WGR | Between 1 October 2026 and 28 February 2027—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | ARIPIPRAZOLE-WGR | between 1 November 2026 and 30 April 2027—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 30 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral | Atenolol-AFT | 6 months stock by reference to usual PBS demand |
| Atenolol | Tablet 50 mg | Oral | APX-Atenolol | 4 months stock by reference to usual demand |
| Atenolol | Tablet 50 mg | Oral | Tensig | 4 months stock by reference to usual demand |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 100 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 18 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 25 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 40 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 60 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
| Atropine | Eye drops containing atropine sulfate monohydrate 10 mg per mL, 15 mL | Application to the Eye | Atropt | 6 months stock by reference to usual PBS demand |
| Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection | Atropine Injection (Bridgewest) | 6 months stock by reference to usual PBS demand |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax | 4 months stock by reference to usual PBS demand |
| Baclofen | Tablet 10 mg | Oral | APO-Baclofen | 3 months stock by reference to usual demand |
| Balsalazide | Capsule containing balsalazide sodium 750 mg | Oral | Colazide | 6 months stock by reference to usual PBS demand |
| Benzathine benzylpenicillin | Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre-filled syringe | Injection | Bicillin L-A | 6 months stock by reference to usual PBS demand |
| Benzathine benzylpenicillin | Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe | Injection | Bicillin L-A | 6 months stock by reference to usual PBS demand |
| Bicalutamide | Tablet 50 mg | Oral | Calutex | between 1 July 2026 to 31 December 2026—0 months stock by reference to usual demand |
| Bortezomib | Powder for injection 3 mg | Injection | DBL Bortezomib | between 1 September 2026 to 30 November 2026—0 months stock by reference to usual demand |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |
| Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | 6 months stock by reference to usual PBS demand |
| Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by Mouth | Pulmicort Turbuhaler | 6 months stock by reference to usual PBS demand |
| Calcium | Tablet 600 mg (as carbonate) | Oral | Calci-Tab 600 | 6 months stock by reference to usual PBS demand |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal-500 | 6 months stock by reference to usual PBS demand |
| Capecitabine | Tablet 500 mg | Oral | Xelabine | 4 months stock by reference to usual demand until 31 March 2027 |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | Keflex | Between 1 October 2026 and 31 March 2027—0 months stock by reference to usual demand |
| Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin-AFT | 300,000 packs of a pack quantity of 5 |
| Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | 6 months stock by reference to usual demand |
| Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone Viatris | 6 months stock by reference to usual demand |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | 6 months stock by reference to usual demand |
| Cefuroxime | Tablet 250 mg (as axetil) | Oral | Zinnat | between 1 November 2026 and 31 December 2026—0 months stock by reference to usual demand |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig | 4 months stock by reference to usual PBS demand |
| Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | Injection | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 100 mg | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 6 months stock by reference to usual PBS demand |
| Chlortalidone | Tablet 25 mg | Oral | Hygroton 25 | 4 months stock by reference to usual PBS demand |
| Choriogonadotropin alfa | Solution for injection 250 micrograms in 0.5 mL pre-filled pen | Injection | Ovidrel | 6 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 10 mg | Oral | Neoral 10 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 100 mg | Oral | APO-Ciclosporin | 2.5 months stock by reference to usual demand |
| Ciclosporin | Capsule 25 mg | Oral | APO-Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 50 mg | Oral | APO-Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
| Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the Ear | Ciloxan | 6 months stock by reference to usual PBS demand |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharmacare Australia Pty Ltd | 4 months stock by reference to usual PBS demand |
| Codeine with paracetamol | Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg | Oral | Paracetamol/Codeine GH 500/30 | between 1 September 2026 to 31 January 2027—0 months stock by reference to usual demand |
| Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral | Dantrium | 6 months stock by reference to usual PBS demand |
| Deferasirox | Tablet 180 mg | Oral | DEFERASIROX-TEVA | between 1 September 2026 to 31 January 2027—0 months stock by reference to usual demand |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Vasocardal CD | between 1 August 2026 and 31 December 2026—0 months stock by reference to usual demand |
| Diphtheria and tetanus vaccine, adsorbed, diluted for adult use | Injection 0.5 mL in pre-filled syringe | Injection | ADT Booster | 6 months stock by reference to usual PBS demand |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | 6 months stock by reference to usual PBS demand |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the Eye | Cosdor | 4 months stock by reference to usual demand until 31 March 2027 |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the Eye | Cosopt | 4 months stock by reference to usual demand until 31 March 2027 |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the Eye | Vizo-PF Dorzolatim | 4 months stock by reference to usual demand until 31 March 2027 |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | 6 months stock by reference to usual demand |
| Doxorubicin - pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxorubicin - pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | 4 months stock by reference to usual demand |
| Doxycycline | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | 4 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | 5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | APO-Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | APO-Enalapril | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Malean | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | 2 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | APO-Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Erlotinib | Tablet 100 mg (as hydrochloride) | Oral | Erlotinib APOTEX | 4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
| Erlotinib | Tablet 100 mg (as hydrochloride) | Oral | ERLOTINIB ARX | after 28 February 2026—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
| Erythromycin | Capsule 250 mg (containing enteric coated pellets) | Oral | Mayne Pharma Erythromycin | 2 months stock by reference to usual demand |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | 4 months stock by reference to usual PBS demand |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX-Escitalopram | 4 months stock by reference to usual demand |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX-Escitalopram | 4 months stock by reference to usual demand |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate | Transdermal | Estalis sequi 50/140 | 6 months stock by reference to usual PBS demand |
| Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | Transdermal | Estalis continuous 50/140 | 6 months stock by reference to usual PBS demand |
| Etoposide | Powder for I.V. infusion 1 g (as phosphate) | Injection | Etopophos | 4 months stock by reference to usual demand until 31 March 2027 |
| Evolocumab | Injection 140 mg in 1 mL single use pre-filled pen | Injection | Repatha | 6 months stock by reference to usual PBS demand |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | APO-Ezetimibe/Simvastatin 10/10 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | APO-Ezetimibe/Simvastatin 10/20 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | APO-Ezetimibe/Simvastatin 10/40 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | APO-Ezetimibe/Simvastatin 10/80 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Felodur ER 2.5 mg | 2.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 16.8 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO-Fentanyl | 3.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |
| Ferrous Sulfate | Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL | Oral | Ferro-Liquid | 6 months stock by reference to usual PBS demand |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
| Fludarabine | Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL | Injection | Fludarabine Ebewe | between 1 November 2026 and 31 November 2026—0 months stock by reference to usual demand |
| Folic acid | Tablet 5 mg | Oral | Megafol 5 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | 4 months stock by reference to usual PBS demand |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral | APO-Fosinopril | 3 months stock by reference to usual demand |
| Fosinopril | Tablet containing fosinopril sodium 20 mg | Oral | APO-Fosinopril | 3 months stock by reference to usual demand |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the Eye/Ear | Soframycin | 4 months stock by reference to usual PBS demand |
| Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 6 months stock by reference to usual PBS demand |
| Fusidic acid | Tablet containing sodium fusidate 250 mg | Oral | Fucidin | 6 months stock by reference to usual PBS demand |
| Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |
| Gabapentin | Tablet 600 mg | Oral | APX-GABAPENTIN | 4 months stock by reference to usual demand of both Gabapentin APOTEX and APX-GABAPENTIN added together |
| Galantamine | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | 1.5 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Glibenclamide | Tablet 5 mg | Oral | Daonil | Between 1 October 2026 and 31 May 2027—0 months stock by reference to usual demand |
| Glimepiride | Tablet 1 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glimepiride | Tablet 2 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glimepiride | Tablet 2 mg | Oral | GLIMEPIRIDE-WGR | between 1 November 2026 and 31 March 2027—0 months stock by reference to usual demand |
| Glimepiride | Tablet 3 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glimepiride | Tablet 4 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glucose and ketone indicator-urine | Test strips, 50 (Keto-Diastix) | For External Use | Keto-Diastix | 4 months stock by reference to usual PBS demand |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual | Nitrolingual Pumpspray | 4 months stock by reference to usual PBS demand |
| Glyeryl trinitrate | Transdermal patch 18 mg | Transdermal | Minitran 5 | between 1 June 2026 to 31 January 2027—0 months stock by reference to usual demand |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Bars 81 g, 7 (Camino Pro Complete) | Oral | Camino Pro Complete | 6 months stock by reference to usual PBS demand |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Oral liquid 250 mL, 30 (PKU Glytactin RTD 15 Lite) | Oral | PKU Glytactin RTD 15 Lite | 6 months stock by reference to usual PBS demand |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Oral liquid 250 mL, 30 (PKU Glytactin RTD 15) | Oral | PKU Glytactin RTD 15 | 6 months stock by reference to usual PBS demand |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 15 g, 30 (PKU Build 10) | Oral | PKU Build 10 | 6 months stock by reference to usual PBS demand |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 32 g, 30 (PKU Build 20) | Oral | PKU Build 20 | 6 months stock by reference to usual PBS demand |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Sachets containing oral powder 40 g, 30 (Camino Pro Bettermilk) | Oral | Camino Pro Bettermilk | 6 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 1.5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 500 micrograms | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Heparin | Injection 5,000 units (as sodium) in 0.2 ml | Injection | DBL Heparin Sodium | 6 months stock by reference to usual PBS demand |
| High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral liquid 250 mL, 30 (KetoVie 3:1) | Oral | KetoVie 3:1 | 6 months stock by reference to usual PBS demand |
| High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral liquid 250 mL, 30 (KetoVie 4:1) | Oral | KetoVie 4:1 | 6 months stock by reference to usual PBS demand |
| High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral liquid 250 mL, 30 (KetoVie Peptide 4:1) | Oral | KetoVie Peptide 4:1 | 6 months stock by reference to usual PBS demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand |
| Imatinib | Tablet 600 mg (as mesilate) | Oral | Imatab | between 1 September 2026 to 30 November 2026—0 months stock by reference to usual demand |
| Indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Insig | 3 months stock by reference to usual demand |
| Insect allergen extract-honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | 6 months stock by reference to usual PBS demand |
| Insect allergen extract-paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | 6 months stock by reference to usual PBS demand |
| Insect allergen extract-yellow jacket venom | Injection set containing 550 micrograms | Injection | Albey Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000) | Oral | Isoleucine 1000 | 0 months stock by reference to usual PBS demand |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50) | Oral | Isoleucine 50 | 0 months stock by reference to usual PBS demand |
| Lamivudine | Tablet 300 mg | Oral | Lamivudine Viatris | 4 months stock by reference to usual demand of both Lamivudine Alphapharm and Lamivudine Viatris added together |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | 4.5 months stock by reference to usual demand |
| Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | 3 months stock by reference to usual demand |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the Eye | APO-Latanoprost | 2 months stock by reference to usual demand |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO-Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand |
| Levetiracetam | Tablet 1 g | Oral | LEVETIRACETAM-WGR | 6 months stock by reference to usual demand |
| Levetiracetam | Tablet 500 mg | Oral | Levetiracetam Viatris | 4 months stock by reference to usual demand of both Levetiracetam Mylan and Levetiracetam Viatris added together |
| Levonorgestrel | Intrauterine drug delivery system 52 mg | Intrauterine | Mirena | 6 months stock by reference to usual PBS demand |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | 6 months stock by reference to usual PBS demand |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |
| Meloxicam | Capsule 7.5 mg | Oral | Mobic | between 1 September 2026 to 31 January 2027—0 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox (Combination Pack) | 6 months stock by reference to usual PBS demand |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 10 mg | Oral | Artige | between 1 January 2026 to 31 December 2026 - 3 months stock by reference to usual demand |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 10 mg | Oral | Ritalin 10 | between 1 January 2026 to 31 December 2026 - 3 months stock by reference to usual demand |
| Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection | Metoclopramide HCl Medsurge | 6 months stock by reference to usual demand |
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | Metrol 100 | 4 months stock by reference to usual demand |
| Metronidazole | Suppositories 500 mg, 10 | Rectal | Flagyl | 6 months stock by reference to usual PBS demand |
| Mifepristone and misoprostol | Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms | Oral | MS-2 Step | 6 months stock by reference to usual PBS demand |
| Milk protein and fat formula with vitamins and minerals -- carbohydrate free | Oral powder 225 g (Carbohydrate Free Mixture) | Oral | Carbohydrate Free Mixture | 6 months stock by reference to usual PBS demand |
| Minocycline | Tablet 50 mg (as hydrochloride) | Oral | Akamin 50 | 6 months stock by reference to usual demand |
| Minocycline | Tablet 50 mg (as hydrochloride) | Oral | Minomycin-50 | 6 months stock by reference to usual demand |
| Modafinil | Tablet 100 mg | Oral | Modafin | 3 months stock by reference to usual demand |
| Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | NARCAN | 4 months stock by reference to usual demand |
| Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | between 1 September 2026 to 31 January 2027—0 months stock by reference to usual PBS demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | APO-Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | APO-Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | 2 months stock by reference to usual demand |
| Norfloxacin | Tablet 400 mg | Oral | APO-Norfloxacin | 2.5 months stock by reference to usual demand |
| Nortriptyline | Tablet 10 mg (as hydrochloride) | Oral | Allegron | between 1 June 2026 to 30 November 2026—4 months stock by reference to usual demand |
| Nortriptyline | Tablet 25 mg (as hydrochloride) | Oral | Allegron | between 1 June 2026 to 30 November 2026—4 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | 3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 2.5 mg | Oral | APO-OLANZAPINE | 6 months stock by reference to usual demand |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO-Olanzapine ODT | 3 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMERTAN | 3 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | 3.5 months stock by reference to usual demand |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 40/10 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/10 added together |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 20/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 40/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMERTAN COMBI 40/25 | 3 months stock by reference to usual demand |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | 6 months stock by reference to usual demand |
| Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | Oxaliplatin Accord | 4 months stock by reference to usual demand until 31 March 2027 |
| Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | OXALIPLATIN BAXTER | 4 months stock by reference to usual demand until 31 March 2027 |
| Oxazepam | Tablet 30 mg | Oral | APO-Oxazepam | 5.5 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |
| Oxybutynin | Transdermal patches 36 mg, 8 | Transdermal | Oxytrol | 6 months stock by reference to usual PBS demand |
| Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL | Oral | OxyNorm Liquid 1mg/mL | 4 months stock by reference to usual PBS demand |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | 4 months stock by reference to usual PBS demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | 5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | 5.5 months stock by reference to usual demand |
| Peginterferon alfa-2a | Injection 135 micrograms in 0.5 mL single use pre-filled syringe | Injection | Pegasys | 6 months stock by reference to usual PBS demand |
| Peginterferon alfa-2a | Injection 180 micrograms in 0.5 mL single use pre-filled syringe | Injection | Pegasys | 6 months stock by reference to usual PBS demand |
| Periciazine | Tablet 10 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | PERISYL | 6 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | PERINDOPRIL-WGR | between 1 November 2026 and 31 March 2027—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | PERISYL | 6 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | 2.5 months stock by reference to usual demand |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | 6 months stock by reference to usual PBS demand |
| Phenelzine | Tablet 15 mg (as sulfate) | Oral | Nardil | 6 months stock by reference to usual PBS demand |
| Pimecrolimus | Cream 10 mg per g, 15 g | Application | Elidel | 6 months stock by reference to usual PBS demand |
| Potassium chloride | Tablet 600 mg (sustained release) | Oral | Span-K | 6 months stock by reference to usual demand |
| Potassium chloride with potassium bicarbonate | Tablet, effervescent, 14 mmol potassium and 8 mmol chloride | Oral | Chlorvescent | 6 months stock by reference to usual demand |
| Probenecid | Tablet 500 mg | Oral | Pro-Cid | 6 months stock by reference to usual PBS demand |
| Prochlorperazine | Injection containing prochlorperazine mesilate 12.5 mg in 1 mL | Injection | Stemetil | 6 months stock by reference to usual PBS demand |
| Propylene glycol | Eye drops 60 micrograms per mL, 10 mL | Application to the Eye | Systane Balance | 4 months stock by reference to usual PBS demand |
| Protein hydrolysate formula with medium chain triglycerides | Oral powder 450 g (Aptamil Gold+ Pepti-Junior) | Oral | Aptamil Gold+ Pepti-Junior | 6 months stock by reference to usual PBS demand |
| Quinapril | Tablet 10 mg (as hydrochloride) | Oral | APO-Quinapril | 3 months stock by reference to usual demand |
| Quinapril | Tablet 20 mg (as hydrochloride) | Oral | APO-Quinapril | 3 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO-Rabeprazole | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | RALOVISTA | 3 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | APX-Ramipril | 5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | 5.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Prilace | 2.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Ramipril Viatris | 3 months stock by reference to usual demand |
| Ramipril | Tablet 10 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
| Ramipril | Tablet 2.5 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
| Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
| Risedronic acid | Tablet containing risedronate sodium 150 mg | Oral | APO-Risedronate | 3 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | APO-Risperidone | 3.5 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APO-ROSUVASTATIN | 6 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN | 6 months stock by reference to usual demand |
| Roxithromycin | Tablet 150 mg | Oral | APX-Roxithromycin | 4 months stock by reference to usual demand |
| Roxithromycin | Tablet 300 mg | Oral | APX-Roxithromycin | 5 months stock by reference to usual demand |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Asmol CFC-Free with dose counter | 4 months stock by reference to usual demand |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Ventolin CFC-Free with dose counter | 4 months stock by reference to usual demand |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Zempreon CFC-Free with dose counter | 4 months stock by reference to usual demand |
| Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline generichealth | between 1 September 2026 to 31 December 2026—0 months stock by reference to usual demand |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | Sevelamer Lupin | between 1 October 2026 to 30 November 2026—0 months stock by reference to usual demand |
| Sildenafil | Tablet 20 mg (as citrate) | Oral | SILDENAFIL PHT APOTEX | Between 1 June 2026 and 31 March 2027—4 months stock by reference to usual demand of both SILDENAFIL PHT ARX and SILDENAFIL PHT APOTEX added together |
| Sildenafil | Tablet 20 mg (as citrate) | Oral | SILDENAFIL PHT ARX | Between 1 June 2026 and 31 March 2027—4 months stock by reference to usual demand of both SILDENAFIL PHT ARX and SILDENAFIL PHT APOTEX added together |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | 6 months stock by reference to usual PBS demand |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | 1.5 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO-Sumatriptan | 4 months stock by reference to usual demand |
| Tacrolimus | Capsule 0.5 mg | Oral | Pacrolim | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Pharmacor Tacrolimus 0.5 | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Prograf | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrograf | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrolimus Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Pacrolim | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Pharmacor Tacrolimus 1 | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Prograf | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Tacrolimus | Capsule 1 mg | Oral | Tacrolimus Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg (once daily prolonged release) | Oral | ADVAGRAF XL | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg (once daily prolonged release) | Oral | Tacrolimus XR Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 3 mg (once daily prolonged release) | Oral | ADVAGRAF XL | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 3 mg (once daily prolonged release) | Oral | Tacrolimus XR Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg | Oral | Pharmacor Tacrolimus 5 | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg | Oral | Prograf | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Tacrolimus | Capsule 5 mg | Oral | Tacrolimus Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg (once daily prolonged release) | Oral | ADVAGRAF XL | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg (once daily prolonged release) | Oral | Tacrolimus XR Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Telmisartan with amlodipine | Tablet 40 mg-10 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 40 mg-10 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 40 mg-5 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 40 mg-5 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 80 mg-10 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 80 mg-10 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 80 mg-5 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Telmisartan with amlodipine | Tablet 80 mg-5 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
| Temazepam | Tablet 10 mg | Oral | APO-Temazepam | 2.5 months stock by reference to usual demand |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 APX | 6 months stock by reference to usual demand |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |
| Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | Pfizer Australia Pty Ltd | 2 months stock by reference to usual demand |
| Topiramate | Tablet 100 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 200 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 25 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 50 mg | Oral | APO-Topiramate | 3 months stock by reference to usual demand |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral | Tramal | 4 months stock by reference to usual PBS demand |
| Trandolapril | Capsule 1 mg | Oral | Dolapril 1 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 2 mg | Oral | Dolapril 2 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 4 mg | Oral | Dolapril 4 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 500 micrograms | Oral | Dolapril 0.5 | 2.5 months stock by reference to usual demand |
| Trastuzumab | Powder for I.V. infusion 420 mg | Injection | Kanjinti | between 1 September 2026 to 30 November 2026—0 months stock by reference to usual demand |
| Triglycerides—medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | 0 months stock by reference to usual PBS demand |
| Triglycerides, long chain with glucose polymer | Oral liquid 1 L, 6 (ProZero) | Oral | ProZero | 0 months stock by reference to usual PBS demand |
| Triglycerides, medium chain | Oil 500 ml (MCT Oil) | Oral | MCT Oil | 6 months stock by reference to usual PBS demand |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | 6 months stock by reference to usual demand |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | 0 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | 0 months stock by reference to usual PBS demand |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | 6 months stock by reference to usual PBS demand |
| Valproic acid | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Syrup | 6 months stock by reference to usual PBS demand |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | between 1 July 2026 to 31 December 2026—0 months stock by reference to usual demand |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Juno | 6 months stock by reference to usual demand |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.